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Brief, 40-word-or-less summary of the article's main point. We have previously associated genetic 
background with chronic kidney disease in people living with HIV (PWH). Here we show that an 




















Background. In people with HIV (PWH), it is unknown whether genetic background associates with 
rapid progression of kidney dysfunction; i.e. eGFR decrease of >5mL/min/1.73m2 per year for >3 
consecutive years. 
Methods. We used time-to-event analyses to measure univariable and multivariable hazard ratios 
(HR) for rapid progression, based on the clinical D:A:D CKD risk score, antiretroviral exposures, and a 
polygenic risk score based on 14’ 6  genome-wide single nucleotide polymorphisms (SNPs) in white 
Swiss HIV Cohort Study participants. 
Results. We included 225 participants with rapid progression (median age 42 years, 76% male, 
median baseline eGFR 101 mL/min/1.73m2) and 3378 rapid progression-free participants. In 
multivariable analysis, compared to participants with a low risk D:A:D CKD risk score, participants 
with medium and high risk had rapid progression-HR=1.30 (0.99-1.71) and 1.82 (1.28-2.60), 
respectively. Compared to the first (most favorable) polygenic risk score quartile, participants in the 
second, third and fourth (most unfavorable) quartiles had rapid progression-HR=1.39 (0.94-2.06), 
1.52 (1.04-2.24) and 2.04 (1.41-2.94), respectively. Recent exposure to tenofovir disoproxil fumarate 
was associated with rapid progression (HR=1.36 [1.06-1.76]). 
Discussion. An individual polygenic risk score is associated with rapid progression in Swiss PWH, 
when analyzed in the context of clinical and antiretroviral risk factors. 
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Chronic kidney disease (CKD) is a considerable concern in people with HIV (PWH). In addition 
to advancing age, risk factors for CKD in PWH include traditional risk factors such as pre-existing 
kidney disease, female gender, injection drug use, cardiovascular disease, hypertension, and 
diabetes[1]. Hypertension was defined as blood pressure >140/90mmHg or use of antihypertensive 
medication. Diabetes mellitus was diagnosed with confirmed plasma glucose >7.0mmol/L (fasting) or 
>11.1mmol/L (non-fasting) or receiving antidiabetic medication. HIV-related factors for CKD include 
the effects of immunosuppression and exposure to potentially nephrotoxic antiretroviral therapy 
(ART) including atazanavir/ritonavir (ATV/r), tenofovir disoproxil fumarate (TDF), and 
lopinavir/ritonavir (LPVr). The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D CKD risk 
score) study, the largest consortium of HIV observational studies with strict endpoint definition and 
validation, has summarized these risk factors in a well validated risk score for CKD, defined as 
confirmed (>3 months apart) eGFR<60 mL/min/1.73m2 [1]. Another, more dynamic measure of 
kidney impairment in PWH is rapid progression of kidney dysfunction, variably defined as annual 
eGFR decline of >3 or >5mL/min/1.73m2 in several consecutive years[2-4]. In comparison, the 
normal age-related rate of eGFR decline is approximately 1 mL/min/1.73m2 per year[5,6]. Studying 
rapid progression is important because, in addition to potentially allowing early detection of kidney 
dysfunction and prediction of progression to CKD in PWH [4], rapid progression has been associated 
with CKD, all-cause and cardiovascular mortality in the general population[6-8]. 
Genome-wide association studies (GWAS) have shown that a significant proportion of CKD 
risk in the general population is genetically determined[9-11]. We have recently shown that a 
polygenic risk score that summarizes the effect of 86’613 single nucleotide polymorphisms (SNPs  
independently predicts CKD in Swiss PWH with normal baseline kidney function[12]. The genetic 
effect remained robust after adjusting for D:A:D CKD risk score and exposure to potentially 
nephrotoxic ART[12]. The contribution of genetic background to rapid progression in PWH is 

















contribution of genetic background, D:A:D CKD risk score, and relevant ART exposures to rapid 
progression. This is the first comprehensive study to apply GWAS genotyping and a longitudinal 
approach that includes validated clinical and antiretroviral risk factors for rapid progression in PWH. 
METHODS 
 
Study Population. Eligible participants were PWH enrolled in the Swiss HIV Cohort Study (SHCS; 
www.shcs.ch) after 1 January 2004[13]. We only considered eGFR values obtained per protocol at 
routine, 6-monthly SHCS visits, with creatinine values measured in local accredited hospital 
laboratories. We included participants who had 2 consecutive eGFR values >80 mL/min/1.73m2 
during follow-up, using the Chronic Kidney Disease Epidemiology Collaboration formula. The study 
was approved by the local ethics committees. Participants provided written informed consent for 
genetic testing. Because previous GWAS focusing on kidney insufficiency in the general population 
were performed in populations of predominantly European ancestry, we limited the study to 
participants of European ancestry, determined by principal component analysis of the genotyping 
data[9-11].  
Nongenetic CKD Risk Factors. Only variables included in the D:A:D CKD risk score [1] were included 
(mode of HIV transmission, hepatitis C co-infection, age, baseline eGFR, gender, CD4 nadir, 
hypertension, prior cardiovascular disease, and diabetes mellitus). All ART agents are recorded in the 
SHCS database with start/stop dates. We adjusted only for those ART exposures that contributed to 
CKD in the D:A:D study[14], i.e. ATV/r, LPV/r, and TDF. As done previously [12], hypertension was 
defined as blood pressure >140/90 mmHg or use of antihypertensive medication; diabetes mellitus 
was diagnosed with confirmed plasma glucose >7.0 mmol/L (fasting) or >11.1 mmol/L (non-fasting) 


















Genotyping. DNA samples were obtained from peripheral blood mononuclear cells and genotyped 
with the Infinium CoreExome-24 BeadChip, Global Screening Array v2.0+MD (Illumina, San Diego, 
CA), or in the setting of previous GWAS in the SHCS. Each genotyping batch underwent separate 
quality controls, filtering and imputation prior to merging of all batches and analyses 
(Supplementary Methods).  
Genome-wide Polygenic Risk Score. Polygenic risk score  for the filtered and imputed samples was 
calculated using the summary statistics and effect sizes from a previous large-scale genetic meta-
analysis of baseline eGFR levels [11]. Specifically, the polygenic risk score was calculated with PRSice 
(v2.3.1e)[15], with clumping removing variants in linkage disequilibrium (LD) (r2 > 0.1)  within 1Mb 
windows and exclusion of ambiguous variants. Variants passing the initial filtering, but missing in 
some individuals were not counted in the score for these individuals.  
Statistical Analyses. The baseline date was defined as the date of the 2nd of 2 consecutive eGFR 
values >80 mL/min/1.73m2. Baseline eGFR was calculated as the average of these 2 eGFR values. 
Compared to our previous report[12], we lowered the eGFR entry criterion to the study from 90 to 
80 mL/min/1.73m2, in order to increase the size of the study population, and to make results more 
broadly applicable to aging PWH. Subsequent follow-up was split into yearly intervals and individual 
eGFR values were averaged for each year of follow-up. We interrupted follow-up when participants 
were switched to integrase inhibitor (INSTI)-containing ART, including raltegravir (RAL), dolutegravir 
(DTG), bictegravir (BIC), or cobicistat (COBI), because these agents can artefactually decrease eGFR 
without decreasing the actual GFR, due to inhibition of creatinine secretion [16,17]. Participants who 
started or switched to INSTI-containing ART could enter or re-enter the study for a second 
observation period with 2 consecutive eGFR >80 mL/min/1.73m2 after starting INSTI; the date of the 
2nd eGFR value, i.e. >6 months after the 1st eGFR value was taken as the new baseline eGFR, in order 

















The study endpoint was defined as the 3rd of 3 consecutive years with an eGFR drop of >5 
mL/min/1.73m2, each compared to the previous year. We subsequently refer to participants who 
reached this endpoint as having rapid progression of kidney dysfunction, as previously published by 
D:A:D investigators[4]; we refer to those who did not reach this endpoint as participants without 
rapid progression. We used time-to-event analyses with follow-up from baseline until the year of the 
event, last eGFR, death, or interruption due to switch to RAL, DTG, BIC, or COBI, whichever occurred 
first. Results were presented as Kaplan-Meier failure plots and Cox proportional hazard regressions. 
Cox models were calculated with robust standard errors, allowing for clustering of participants who 
entered the analyses both before and after switching to RAL, DTG, BIC, or COBI. The main exposures 
of interest were the D:A:D CKD risk score[1], stratified into low, medium and high risk, and the 
quartiles of the polygenic risk score. Interactions between D:A:D CDK risk score and polygenic risk 
score were analysed using the likelihood-ratio test. As additional co-variables we included time-
updated exposure to potentially nephrotoxic ART agents until the rapid progression date in 
participants with rapid progression and until the date of last follow-up in the SHCS in participants 
without rapid progression. We considered both cumulative exposure to ART agents associated with 
increased CKD incidence in the D:A:D stu y[14], and recent exposure, defined as treatment in the 6 
months before the rapid progression date. We also performed a Kaplan-Meier analysis to document 
how rapid progression translates into confirmed CKD, defined as the 2nd of 2 consecutive eGFR 
values <60 mL/min/1.73m2 [12]. Analyses were done with Stata/SE 16.1 (StataCorp, College Station, 
Texas).  
Sensitivity Analyses. To ascertain the applicability of results to PWH with a wider range of baseline 
eGFR, we performed 3 separate sensitivity analyses: First, we included tertiles of baseline eGFR as 
additional variable in the models; second, we expanded inclusion to participants with baseline eGFR 


















Exploratory genome-wide association analysis. In an exploratory GWAS, we tested all SNPs on the 
genetic arrays for association with rapid progression (Supplementary Methods).  
RESULTS 
 
Participants. We analyzed 3603 SHCS participants, including 225 participants with rapid progression 
and 3378 participants without rapid progression. 26 participants with rapid progression and 716 
participants without rapid progression contributed twice to the analyses, i.e. during a first 
observation period without INSTI/COBI and a second observation period during INSTI/COBI 
exposure. All subsequent analyses are therefore based on 4345 observation periods (251 periods 
with an rapid progression event and 4094 periods without rapid progression . The participants’ 
baseline characteristics are shown in Table 1. Among the participants with rapid progression, 
compared to those without rapid progression, there were fewer men, CD4+ and CD4+ nadir counts 
were lower, there were slightly more participants with HCV co-infection, diabetes, injection drug 
use, and there were fewer participants in the low risk D:A:D category. Participants with rapid 
progression had higher genetic risk than those without rapid progression, as indicated by 
participants with rapid progression being overrepresented in the 4th (most unfavorable) polygenic 
risk score quartile (Figure 1). As exp cted, at the baseline date of potential second observation 
periods, participants were older, eGFR was lower, and the prevalence of “high risk” D:A:D CKD risk 
scores was higher than at the baseline date of the first period. 
 
Polygenic Risk Score. Following p-value thresholding, the final model included 14,769 independent 



















Probability of rapid progression According to Clinical D:A:D CKD Risk Score, Polygenic Risk Score, 
and ART: Univariable Analysis. rapid progression probability was significantly associated with D:A:D 
CKD risk score (test for trend, p=0.003) and polygenic risk score (test for trend, p<0.001) (Figure 2). 
Compared to the low risk D:A:D CKD risk score, participants with medium and high D:A:D risk had a 
rapid progression hazard ratio (rapid progression -HR) of 1.26 (95% CI, 0.96-1.65) and 1.75 (1.23-
2.48), respectively. Compared to the first (most favorable) polygenic risk score quartile, participants 
in the second, third and fourth (most unfavorable) quartiles had rapid progression -HR of 1.35 (0.91-
1.99), 1.46 (0.99-2.15) and 1.96 (1.36-2.83), respectively. There was no evidence for an association 
of cumulative exposure to TDF, ATV/r and LPV/r with rapid progression, with HR=1.15 (0.96-1.39), 
1.02 (0.79-1.31) and 0.97 (0.76-1.24), respectively. Recent exposure to TDF was associated with 
rapid progression (HR=1.37; 1.06-1.77), but there was no evidence for an association of recent 
exposure to ATV/r and LPV/r with rapid progression (rapid progression -HR=1.36; 0.99-1.87, and 
1.06; 0.71-1.59, respectively). 
 
Probability of Rapid Progression According to Clinical D:A:D CKD Risk Score, Polygenic Risk Score, 
and ART: Multivariable Analyses. Rapid progression was associated with the D:A:D CKD risk score, 
polygenic risk score, and recent TDF exposure (Figure 3). Compared to participants with a low risk 
D:A:D CKD risk score, participants with a medium and high risk D:A:D CKD risk score had rapid 
progression -HR of 1.30 (0.99-1.71) and 1.82 (1.28-2.60), respectively. Compared to the first (most 
favorable) polygenic risk score quartile, participants in the second, third and fourth (most 
unfavorable) quartiles had rapid progression -HR=1.39 (0.94-2.06), 1.52 (1.04-2.24) and 2.04 (1.41-
2.94), respectively. Recent exposure to TDF was associated with rapid progression, with HR=1.36 
(1.06-1.76). There was no evidence for an association of recent exposure to ATV/r or LPV/r, with 
rapid progression-HR=1.30 (0.95-1.79) and 1.11 (0.73-1.67), respectively), and no evidence for an 
association of cumulative exposure to TDF, ATV/r, and LPV/r with rapid progression, with HR=1.12 


















Rapid progression Probability, Interaction of D:A:D CKD Risk Score and Polygenic Risk Score. When 
we applied an interaction term between the D:A:D CKD risk score and polygenic risk score, the 
model fit did not improve. (Supplementary Tables 1 and 2) 
 
Rapid progression predicts CKD. Of all 4345 observation periods analyzed, 99/251 (39.5%) with rapid 
progression and 475/4094 (11.6%) without rapid progression progressed to CKD, defined as 
confirmed eGFR<60 mL/min/1.73m2. The 5-year and 10-year probability of CKD was 14% (10-19%) 
and 34% (28-41%), respectively, in participants with rapid progression, and 3% (2-3%) and 9% (8-
11%), respectively, in participants without rapid progression. The time until 10% of participants with 
and without rapid progression experienced CKD was 4.1 (2.8-4.8) and 10.3 (9.9-10.8) years, 
respectively (Figure 4).  
Sensitivity Analyses with different baseline eGFR in the models. In order to evaluate whether the 
polygenic risk score association with rapid progression applies to various levels of baseline kidney 
function, we redefined the study population as participants with baseline eGFR >70 mL/min/1.73m2  
(n=4700) and as participants with baseline eGFR >90 mL/min/1.73m2  (n=3423), with similar results 
(Supplementary Table 3). In an additional sensitivity analysis, we separated the study population 
into 3 tertiles according to baseline eGFR. This led only to modest effect modification 
(Supplementary Table 4). Median (IQR) eGFR at baseline was 89 (80-95), 100 (95-106), and 113 
(106-181) mL/min/1.73m2, in the 3 tertiles, respectively. In multivariable analysis including tertiles of 
baseline eGFR, results remained essentially unchanged; participants in the 2nd, 3rd, and 4th 
polygenic risk score quartiles had rapid progression -HR=1.42 (0.96-2.11), 1.54 (1.04-2.27), and 2.05 


















Exploratory GWAS. In the exploratory GWAS, we did not observe any genome-wide significant 
association. However, we were able to nominally replicate (p<0.05) 2 of the genome-wide significant 
SNPs that were reported to be genome-wide significant in the general population, each with p=0.03 
and the same direction of the effect in this dataset and in the reference paper[11]: rs56019566 
(chromosome 2; BP 15788692; p=1.08E-10 in[11]) and rs1111571 (chromosome 16, BP 68363181; 
p=6.20E-09 in[11]) (Supplementary Figures 1-3). This low number of replicated SNPs is as expected: 
All the previous genome-wide significant individual SNPs have very low effect sizes[11], thus 
replication cohorts with very large sample sizes would be required to capture their effect well.  
DISCUSSION 
 
Here we describe, for the first time to our knowledge, that an unfavorable polygenic risk score 
increases the probability of rapid progression of kidney dysfunction in PWH approximately 2-fold. 
This extends our previous result that a GWAS-derived polygenic risk score is associated with CKD in 
PWH [12]. We found a robust association of unfavorable polygenic risk score with rapid progression: 
The polygenic risk score effect persisted after adjusting for multiple clinical risk factors that are 
summarized in the well validated D:A:D CKD risk score, and after considering the effect of 
antiretroviral agents with nephrotoxic potential[1,14,18]. Because eGFR>80 mL/min/1.73m2 at 
baseline is ultimately an arbitrary threshold, we also used different baseline eGFR definitions in 
sensitivity analyses: polygenic risk score remained associated with rapid progression in participants 
in all 3 tertiles of baseline eGFR, and also when we variably defined baseline kidney function as eGFR 
>70, >80, and >90 mL/min/1.73m2, respectively. Our finding of a significant association of genetic 
background with rapid progression in PWH is consistent with recently reported results of a GWAS 
meta-analysis in the general population[11,19]. 
 
We exploited prospectively collected clinical, laboratory and HIV-related data of 3603 HIV+ 

















polygenic risk score, D:A:D CKD risk score and ART. We applied the stringent rapid progression 
definition proposed by the D:A:D study [4], i.e. an eGFR drop of >5 mL/min/1.73m2 per year for >3 
consecutive years. We show that, rather than representing only a subtle degree of kidney 
impairment, rapid progression increases the probability more than 2-fold of progressing to CKD. This 
underlines the clinical importance of also considering a more dynamic measure of kidney 
impairment (i.e. declines in kidney function that are sustained over several years) in addition to the 
more static CKD endpoints to evaluate kidney dysfunction risk in PWH[12].  
 
We identified an approximately 2-fold increased rapid progression hazard ratio, both for genetic 
background (polygenic risk score) and for clinical D:A:D CKD risk score, and a 36% increased rapid 
progression hazard ratio for recent TDF exposure in multivariable analysis. The effect size of genetic 
background on rapid progression risk therefore appears larger than the effect size of potentially 
nephrotoxic ART. Alternatively, the dynamics of the different risk factors on the development of 
kidney impairment may differ. Potentially nephrotoxic ART and clinical CKD risk factors such as 
diabetes mellitus may cause a gradual loss of nephrons and therefore a slow decline of eGFR, with 
the nephrotoxic effect typically becoming apparent only after accumulating years of exposure. This 
slow loss of kidney function may not fulfill rapid progression criteria and may explain why we did not 
identify an association of cumulative exposure to TDF, ATV/r, and LPV with rapid progression, 
whereas cumulative ART was associated with CKD in our previous report[12]. This also echoes the 
findings of the Veterans Health Study, where cumulative TDF exposure had a smaller effect on rapid 
progression risk than on CKD risk[2]. In contrast, an unfavorable genetic background may become 
clinically apparent as a rapid kidney dysfunction progression pattern, i.e. rapid progression.  
 
It was beyond the scope of our study to assess the clinical value of genetic testing (this will require 
prospective trials), nonetheless, our findings suggest how determination of an individual polygenic 

















background significantly increases rapid progression risk approx. 1.5-fold (3rd polygenic risk score 
quartile) and 2-fold (4th polygenic risk score quartile), respectively, may suggest paying particular 
attention to optimal control of hypertension and diabetes, and to avoiding potentially nephrotoxic 
medication, including TDF and nonsteroidal anti-inflammatory agents. On the other hand, one might 
speculate that a favorable genetic background might argue against reflexive switching of all PWH 
from TDF to less nephrotoxic tenofovir alafenamide (TAF), providing an argument in addition to the 
emerging metabolic toxicities of TAF (obesity, dyslipidemia[20]), and in addition to the efficacy of 
dolutegravir-lamivudine-containing dual ART combinations that is now well recorded[21,22]. In 
addition to clinical kidney disease prediction, our results may inform future research. For example, 
detailed pathway analyses based on genetic information may provide additional pathogenic insights 
into rapid progression, and applying polygenic risk scores may inform the selection of PLW at 
increased risk for attaining appropriate endpoints in clinical trials. 
 
In our previous CKD-GWAS study in Swiss PWH [12], we excluded INSTI-treated participants in the 
main analysis, in order to separate true longitudinal GFR decline from the well recorded INSTI effects 
on estimated GFR[16,17]. In the present study, we included episodes of INSTI-treatment by re-
calculating a “new baseline” eGFR for each participant after starting INSTI therapy. This is important 
because rapid progression prediction by determination of an individual polygenic risk score appears 
broadly applicable also to modern INSTI-based ART. Longitudinal modeling through episodes of 
switching ART, as shown in our previous genetic-dyslipidemia studies [23-25], represents a powerful 
approach to quantifying the individual contribution of multiple intervening factors of relevance to 
eGFR. Other strengths of our study are that we restricted all analyses to gene variants based on 
GWAS, and that we restricted eGFR assessments to the per-protocol semi-annual measurements of 
kidney function at routine SHCS patient visits, in order to avoid confounding by intercurrent illness 
and its treatment. Our study also has limitations. We included only participants of European 

















descent[9-11]. It is important to note, however, that previous genetic studies of CKD in PLW of 
African ancestry have solidly established APOL1 gene variants as risk factors for HIV-associated 
nephropathy and other types of kidney disease[26,27]. Our population was 81% male and, with a 
median baseline age of 42 years, was relatively young. Thus, our results should only cautiously be 
extrapolated to elderly PWH. Also, we did not analyze any genetic associations with proteinuria, 
suggesting an important area of future research in PWH. 
 
In conclusion, some PWH experience rapidly deteriorating kidney dysfunction and our analyses 
reveal an independent contribution of an individual polygenic risk score to explaining interindividual 
variation in rapid progression. We extend our previous observation that genetic background 
associates with CKD risk [12] and highlight the importance of longitudinal study design, in order to 
quantify the effect size of polygenic risk score on rapid progression, in the context of multiple 
shifting environmental risk factors, most notably clinical D:A:D CKD risk score and potentially 
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Table 1. Baseline Characteristics of 3603 Study Participants with and without Rapid 
Progression of Kidney Dysfunction.  





































Male sex 171 (76) 16 (62) 2757 (82) 587 (82) 





101 (93-111) 95 (88-102) 101 (93-110) 95 (88-102) 












Observation time, years, median (IQR) 10 (8-13) 6 (4-7) 10 (6-12) 4 (2.5-6) 
Presumed mode of HIV transmission     
       Heterosexual 75 (33) 928 (27) 
       MSM 96 (43) 1676 (50) 
       IDU 50 (22) 650 (19) 
       other 4 (2) 124 (4) 
Duration of ATV/r treatment, years, 
median (IQR) 
 
       All participants  0 (0-1.6) 0 (0-0.67) 0 (0-1.5) 0 (0-2.27) 
       Ever exposed  2.3 (0.9-4.3) 3.5 (1.4-6.8) 4.0 (1.4-7.4) 3.9 (1.4-7) 
Duration of LPV/r treatment, years, 
median (IQR) 
 
       All participants  0 (0-1.5) 0 (0-1.10) 0 (0-1.3) 0 (0-2) 
       Ever exposed 2.7 (1.1-4.8) 2.4 (0.7-4.1) 2.7 (0.9-6.3) 2.6 (1-6.2) 
Duration of TDF treatment, years, 
median (IQR) 
 
       All participants  3.5 (1.7-6.0) 5.8 (1.9-8.3) 5.5 (1.2-8.7) 6.2 (2.8-9) 
       Ever exposed 3.9 (2.4-6.4) 6.7 (3.9-8.8) 6.7 (3.7-9.4) 7 (4.7-9.7) 
CD4+ count, cells/μL, median (IQR) 436 (291-580) 425 (320-1026) 429 (295-594) 654 (483-842) 
CD4+ count nadir, cells/μL, median 
(IQR) 
200 (89-327) 142 (54-233) 200 (70-333) 177 (60-278) 
Hepatitis C co-infection 71 (32) 9 (35) 998 (30) 215 (30) 
Current
a
 smoking 126 (56) 16 (62) 1979 (59) 410 (57) 
Hypertension 37 (16) 10 (38) 587 (17) 234 (33) 

















Diabetes mellitus 11 (5) 9 (35) 97 (3) 38 (5) 
D:A:D CKD Risk Score  
       Low risk 119 (53) 4 (15) 1926 (57) 242 (34) 
       Medium risk 74 (33) 12 (46) 1071 (32) 282 (39) 
       High risk 32 (14) 10 (38) 381 (11) 192 (27) 
 
Note. Characteristics are shown at baseline dates of first and second observation period, respectively, unless otherwise 
indicated. Data are presented as no. (%) of participants unless otherwise indicated. 
a 
at baseline +/- 1 year.  Abbreviations. 
ATV/r, atazanavir/ritonavir; CKD, chronic kidney disease; COBI, cobicistat; eGFR, estimated glomerular filtration rate; IDU, 
injection drug use; INSTI, integrase-inhibitor containing antiretroviral therapy; IQR, interquartile range; LPV/r, 


















Figure 1. Distribution of Polygenic Risk Score in 3378 Participants without Rapid 
Progression (white bars) and in 225 Participants with Rapid Progression of Kidney 
Dysfunction (black bars)  
 
We divided study participants into 4 quartiles according to their individual polygenic risk score and 
show here the percentage and 95% confidence intervals of participants in each quartile. Among all 
3603 participants, 898 (24.9%), 898 (24.9%), 901 (25%), and 906 (25.2%) were in the 1st (most 
favorable), 2nd, 3rd, and 4th (most unfavorable) polygenic risk score quartile, respectively. Among the 
3378 participants without rapid progression, 859 (25.4%), 844 (25%), 842 (24.9%), and 833 (24.7%) 
were in the 1st, 2nd, 3rd, and 4th polygenic risk score quartile, respectively. Among the 225 participants 
with rapid progression, 39 (17.3%), 54 (24%), 59 (26.2%), and 73 (32.4%) were in the 1st, 2nd, 3rd, and 




















Figure 2. Kaplan-Meier Failure Curves showing the Probabilities of Rapid Progression of 
Kidney Dysfunction according to D:A:D CKD Risk Score (first panel) and Polygenic Risk 




Kaplan-Meier Failure Curves showing the Probabilities of Rapid Progression of Kidney Dysfunction 
according to D:A:D CKD Risk Score (first panel) and Polygenic Risk Score (second panel). Test for 



















Figure 3. Probability of Rapid Progression of Kidney Dysfunction According to Polygenic 




Results are represented as the estimated effect and 95% confidence interval on the hazard ratio and 
95% confidence interval for rapid progression of kidney dysfunction in univariable (white circles) and 
multivariable (black boxes) cox proportional hazard regression models, adjusted for all variables 
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Figure 4. Kaplan-Meier Failure Curve from Baseline to CKD or last eGFR Determination 
(whichever occurred first). 
 
Kaplan-Meier Failure Curves from Baseline to CKD or last eGFR Determination (whichever occurred 
first), stratified by whether Participants had Rapid Progression or not. The shaded areas denote the 
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